A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity

ConclusionsThese findings hold promise for the development of effective weight loss interventions in this population group. There is a need for more phase III studies to provide sufficient clinical evidence for the effectiveness of retatrutide, as current evidence is limited to phase II studies and has yet to prove its worth in a larger population. Here, we aimed to provide an overview of retatrutide's safety and effectiveness in treating obesity.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research